A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study

Key facts

Study ID

NCT02406261

Run by

AstraZeneca

People needed

82

Starts

2015-04-30

Expected to finish

2015-08-31

Last updated by the study team

2019-11-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Overtly healthy and either sterile or, male and prepared to use an approved method of contraception
• Have a body mass index (BMI) at screening of 19.0 to 32.0 kilogram per square meter (kg/m\^2)

You may not qualify if…

• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the results, or may limit the subject's ability to participate in the study
• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• History of previous or ongoing psychiatric disease/condition

Where it is running

• Covance Inc — Daytona Beach, Florida, United States
• Covance Inc — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.